Back

Select your region

Schedule a cord blood consultation

Make an appointment

Stem Cells
Therapies

Stem Cells Therapies

The purpose of banking stem cells is to apply them in the therapy. For the first time cord blood was used in 1988 and since then according to publicly available statistics it has been used over 85 000 times worldwide (including statistics of China).

FamiCord Group stores over 1,000,000 samples of cells of different types and has supplied stem cells for application in clinic for more than 7000 patients. We supply stem cells for standard transplantations (cord blood , bone marrow and mobilized peripheral blood) and cellular therapies. On top of that we provide cell based products in GMP standard for clinical trials.

Stem cells manufactured in our premises helped patients with various diseases and therapeutic areas, including haematological, neurological, ophthalmological, orthopaedical, dermatological disorders.

Check the full list of patients who received stem cell therapy derived from FamiCord labs.

List last update: 06.2026

List of patients who received stem cells from FamiCord Group laboratories

List of patients who received stem cells from FamiCord Group laboratories
Lp. Source Source type Diagnosis Medical field Year of application Therapy Country Age of recipient
1801 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 67
1802 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 65
1803 Apheresis Allogeneic Myelodysplastic Syndrome + Myeloma Hematology 2024 Standard Therapy Germany 67
1804 Apheresis Allogeneic Myelofibrosis Hematology 2024 Standard Therapy Poland 40
1805 Apheresis Allogeneic Myelofibrosis Hematology 2024 Standard Therapy Poland 58
1806 Apheresis Allogeneic Myelofibrosis Myeloid Metaplasia Hematology 2024 Standard Therapy Poland 60
1807 Apheresis Allogeneic Myelofibrosis Post. Polycythemia Vera Hematology 2024 Standard Therapy Poland 66
1808 Apheresis Allogeneic Myelofibrosis With Myeloid Metaplasia Hematology 2024 Standard Therapy Poland 67
1809 Apheresis Allogeneic Myeloma Hematology 2024 Standard Therapy Germany 65
1810 Apheresis Allogeneic Myeloproliferative Neoplasms  Hematology 2024 Standard Therapy Poland 74
1811 Apheresis Allogeneic Myeloproliferative Neoplasms/Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 68
1812 Apheresis Autologous Non-Hodgkin Lymphoma Hematology 2024 Standard Therapy Germany 23
1813 Apheresis Autologous Non-Hodgkin Lymphoma Hematology 2024 Standard Therapy Germany 50
1814 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2024 Standard Therapy Poland 50
1815 Apheresis Autologous Non-Hodgkin Lymphoma Hematology 2024 Standard Therapy Germany 67
1816 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2024 Standard Therapy Poland 46
1817 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2024 Standard Therapy Poland 65
1818 Apheresis Autologous Non-Hodgkin Lymphoma Hematology 2024 Standard Therapy Germany 66
1819 Apheresis Autologous Non-Hodgkin Lymphoma – relapse Hematology 2024 Standard Therapy Germany 54
1820 Apheresis Autologous Nonseminoma Hematology 2024 Standard Therapy Germany 38
1821 Apheresis Allogeneic Osteomyelitis Hematology 2024 Standard Therapy Poland 65
1822 Apheresis Allogeneic Post-Et-Myelofibrosis Hematology 2024 Standard Therapy Poland 59
1823 Apheresis Allogeneic Post-Pv-Myelofibrosis Hematology 2024 Standard Therapy Poland 64
1824 Apheresis Autologous Primary Central Nervous System Lymphoma Hematology 2024 Standard Therapy Germany 60
1825 Apheresis Allogeneic Primary Myelofibrosis Hematology 2024 Standard Therapy Poland 52
1826 Apheresis Allogeneic Primary Myelofibrosis Hematology 2024 Standard Therapy Poland 67
1827 Apheresis Allogeneic Primary Myelofibrosis Hematology 2024 Standard Therapy Poland 70
1828 Apheresis Allogeneic Relapsed B-Cell Acute Lymphoblastic Leukemia Hematology 2024 Standard Therapy Poland 12
1829 Apheresis Allogeneic Severe Aplastic Anemia Hematology 2024 Standard Therapy Poland 15
1830 Apheresis Allogeneic Severe Aplastic Anemia Hematology 2024 Standard Therapy Poland 10
1831 Apheresis Allogeneic Severe Aplastic Anemia Hematology 2024 Standard Therapy Poland 60
1832 Apheresis Allogeneic Severe Aplastic Anemia Progressed To Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 21
1833 Apheresis Autologous Multiple myeloma Hematology 2024 Standard Therapy Germany 63
1834 Apheresis Allogeneic Acute myeloid leukemia Hematology 2024 Standard Therapy Germany 64
1835 Apheresis Autologous Multiple myeloma Hematology 2024 Standard Therapy Germany 56
1836 Apheresis Autologous Hodgkin Lymphoma Hematology 2024 Standard Therapy Germany 56
1837 Apheresis Autologous Multiple myeloma Hematology 2024 Standard Therapy Germany 64
1838 Apheresis Autologous Multiple myeloma Hematology 2024 Standard Therapy Germany 56
1839 Apheresis Autologous Follicular lymphoma Hematology 2024 Standard Therapy Germany 58
1840 Apheresis Autologous Multiple myeloma Hematology 2024 Standard Therapy Germany 65
1841 Apheresis Autologous Multiple myeloma Hematology 2024 Standard Therapy Germany 47
1842 Apheresis Autologous Multiple myeloma Hematology 2024 Standard Therapy Germany 69
1843 Apheresis Autologous Hodgkin Lymphoma Hematology 2024 Standard Therapy Germany 38
1844 Apheresis Autologous Multiple myeloma Hematology 2024 Standard Therapy Germany 65
1845 Apheresis Autologous Multiple myeloma Hematology 2024 Standard Therapy Germany 70
1846 Apheresis Autologous Multiple myeloma Hematology 2024 Standard Therapy Germany 64
1847 Apheresis Autologous Multiple myeloma Hematology 2024 Standard Therapy Germany 53
1848 Apheresis Autologous Multiple myeloma Hematology 2024 Standard Therapy Germany 60
1849 Apheresis Autologous Multiple myeloma Hematology 2024 Standard Therapy Germany 59
1850 Apheresis Autologous Mantle cell lymphoma Hematology 2024 Standard Therapy Germany 45
1851 Apheresis Autologous Multiple myeloma Hematology 2024 Standard Therapy Germany 66
1852 Apheresis Autologous Hodgkin Lymphoma Hematology 2024 Standard Therapy Germany 33
1853 Apheresis Autologous Multiple myeloma Hematology 2024 Standard Therapy Germany 64
1854 Apheresis Autologous Multiple myeloma Hematology 2024 Standard Therapy Germany 59
1855 Apheresis Allogeneic Primary myelofibrosis Hematology 2024 Standard Therapy Germany 55
1856 Apheresis Allogeneic Acute myeloid leukemia Hematology 2024 Standard Therapy Germany 63
1857 Apheresis Allogeneic Blastic Plasmacytoid Dendritic Hematology 2024 Standard Therapy USA 57
1858 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2024 Standard Therapy Poland 32
1859 Apheresis Allogeneic Macrofocal multiple myeloma  Hematology 2024 Standard Therapy USA 75
1860 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy United Kingdom 62
1861 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy USA 52
1862 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Germany 48
1863 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy United Kingdom 71
1864 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Romania 35
1865 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Lithuania 47
1866 Apheresis Allogeneic Diffuse large B-cell lymphoma Hematology 2024 Standard Therapy Australia 46
1867 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy USA 65
1868 Apheresis Allogeneic Chronic lymphatic leukemia Hematology 2024 Standard Therapy Norway 52
1869 Apheresis Allogeneic Chronic myelogenous leukemia Hematology 2024 Standard Therapy Poland 60
1870 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Hungary 32
1871 Apheresis Allogeneic Malignant histiocytosis Hematology 2024 Standard Therapy Bulgaria 41
1872 Apheresis Allogeneic Myelodysplastic syndrome Hematology 2024 Standard Therapy USA 78
1873 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2024 Standard Therapy Hungary 20
1874 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Italy 58
1875 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Portugal 67
1876 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Italy 63
1877 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Lithuania 19
1878 Apheresis Allogeneic Hodgkin lymphoma Hematology 2024 Standard Therapy Russia 34
1879 Apheresis Allogeneic chronic lymphocytic leukemia Richters Transformation Hematology 2024 Standard Therapy United Kingdom 68
1880 Apheresis Allogeneic Myelodysplasia Hematology 2024 Standard Therapy Sweden 66
1881 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Italy 52
1882 Apheresis Allogeneic Myelodysplasia Hematology 2024 Standard Therapy Lithuania 70
1883 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2024 Standard Therapy Germany 72
1884 Apheresis Allogeneic plasma cell leukemia Hematology 2024 Standard Therapy USA 59
1885 Apheresis Allogeneic Fibrolamellar Carcinoma Hematology 2024 Standard Therapy Czechia 41
1886 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Italy 59
1887 Apheresis Allogeneic post-ET Myelofibrose Hematology 2024 Standard Therapy Austria 61
1888 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy USA 55
1889 Apheresis Allogeneic Myeloma Multiplex Hematology 2024 Standard Therapy Poland 67
1890 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Spain 45
1891 Apheresis Allogeneic Myelofibrose Hematology 2024 Standard Therapy Spain 69
1892 Apheresis Allogeneic Myelofibrose Hematology 2024 Standard Therapy Poland 60
1893 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2024 Standard Therapy USA 53
1894 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy France 35
1895 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Italy 69
1896 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Norway 18
1897 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2024 Standard Therapy Germany 51
1898 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 62
1899 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Hungary 56
1900 Apheresis Allogeneic Severe Aplastic Anemia Hematology 2024 Standard Therapy USA 19